RingCentral's stock plunges despite revenue, earnings beat
RingCentral Inc.'s (RNG) stock is getting creamed, down more than 10% in extended trading Monday. The cloud-based phone system provider for small businesses reported a fiscal second-quarter net loss of $21.5 million, or 23 cents a share, compared with a net loss of $159.5 million, or $1.68 a share, in the year-ago quarter. Adjusted earnings were 83 cents a share. Revenue rose 11% to $539.3 million from $486.9 million a year ago. Analysts surveyed by FactSet had expected on average adjusted net earnings of 75 cents a share on revenue of $536.2 million. RingCentral offered full-year revenue guidance of between $2.19 billion and $2.2 billion, roughly in line with analyst estimates. Shares of RingCentral have climbed 10% so far this year, while the broader S&P 500 index has increased 18%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-07-23 1707ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?